FDG-PET screening for cerebral metastases in patients with suspected malignancy

Nuclear Medicine Communications

Volumn 17, Issue 3, 1996, Pages 197-198

  Larcos, G ^a   Maisey, M N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; SOFT TISSUE SARCOMA; TESTIS CANCER;

EID: 0029927549     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006231-199603000-00004     Document Type: Article

References (4)

1. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 31: 623-648.
2. Van Gorp WG, Mandellkern MA, Gee M et al. Cerebral metabolic dysfunction in AIDS: Findings in a sample with and without dementia. J Neuropsychiatr Clin Neurosci 1992; 4: 280-287.
3. Harrison MJG. Neurological complications of systemic diseases. In: Weatherall DJ, Ledingham LGG, Warrell DA, eds. Oxford textbook of medicine. Oxford: Oxford University Press, 1986: 245-246.
4. Lewis P, Griffin S, Marsden P et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.